PROJECT SUMMARY/ABSTRACT: Tumors of the central nervous system (CNS) are the leading cause of cancer death in children. Many of those who do survive suffer from significant lifelong morbidity due to toxicity of therapy. There is an urgent need to improve survival and decrease toxicity of therapy in children with brain tumors. My research focus is to improve survival for children with CNS tumors through the development of novel therapeutics and clinical trials based on biologic insights into the molecular drivers of disease. I conduct my research through collaborative studies that are made possible by the National Clinical Trials Network (NCTN), specifically the Children’s Oncology Group (COG). Nationally, I serve in a leadership role as the clinical vice-chair of the COG CNS committee, COG representative to the NIH Brain Malignancies Steering Committee (BMSC), and CNS representative to the Agent Prioritization Committee (APC) of the NIH-funded Pediatric Early Phase Clinical Trials Network (PEP-CTN). I have also recently led the creation of a data-sharing initiative called the INSPiRE consortium which aims to facilitate clinical trials and genomic data sharing between the COG and other international clinical trials consortia and registries. Locally, I serve as the Seattle Children’s Hospital site PI for COG, Medical Director of Clinical Research for the Seattle Children’s Ben Towne Center for Childhood Cancer Research, Principal Investigator of the Seattle Children’s Tumor Banking and Biology Study, and Medical Director of the Pediatric Brain Tumor Program. These complementary national and local roles allow me to provide support to a wide range of translational and clinical research efforts, providing access to all phases of research to children in Seattle and translating research discovery in Seattle to children across the world through the development of collaborative clinical trials. The opportunities afforded by this award would allow me to devote significant time to accelerate the development of high-impact clinical trials and to support critical efforts to improve molecular and clinical data sharing and local access to trials.